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the ordered probit scale was conducted to evaluate the comparative efﬁ cacy of 
the biologics based on the Psoriasis Area and Severity Index (PASI) responder end-
points. The absolute probability of PASI 50, 75 and 90 responses were estimated. 
RESULTS: A total of 20 studies enrolling 10,108 psoriasis patients, including 1 head-
to-head trial of etanercept and ustekinumab, were identiﬁ ed and included in the NMA.
Thirteen studies evaluated TNF-alpha inhibitors (adalimumab  3, etanercept  6, 
inﬂ iximab  4), 5 studies evaluated T-cell modulators (efalizumab  5), and 3 studies 
evaluated ustekinumab. Baseline patient characteristics were comparable across the
trials. The estimated mean PASI 75 responses were as follows: inﬂ iximab (mean 80%;
95% CI 70–87%), ustekinumab 90 mg (74%; 68–80%), ustekinumab 45 mg (69%; 
62–75%), adalimumab (58%; 49–68%), etanercept 50 mg biw (52%; 45–59%), 
etanercept 25 mg biw (39%; 30–48%), efalizumab (26%; 21–32%), and supportive 
care/placebo (4%; 3–4%). CONCLUSIONS: Based on this analysis, all of the active 
treatments produced a greater response rate than placebo. Ustekinumab and inﬂ ix-
imab had the highest mean response rates followed in order by adalimumab, etaner-
cept and efalizumab. However, there was considerable overlap in the 95% conﬁ dence
intervals.
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OBJECTIVES: Acute otitis media (AOM) is a common childhood condition with viral
and bacterial causation. Routine immunization programs currently include 7-valent 
Pneumococcal Conjugate Vaccine (PCV-7), associated with AOM reduction caused by 
Streptococcus pneumoniae only. The study objective was to conduct a systematic lit-
erature review to identify current microbiological picture associated with AOM. 
METHODS: OVID (Medline, Current Content and International Pharmaceutical
Abstract databases), EMBASE, Google and Google Scholar engines were searched with
the following combination of key-words: “acute otitis media”, “bacteria$” and
“vir$”. Eligible articles were in English, published between 1995 and 2008, and 
described studies of pediatric AOM patients with cultures for bacterial and viral iso-
lates. RESULTS: Of the 398 articles screened, 24 separate studies were included (range
 25–623 subjects). Based on a ﬁ xed-effects meta-analysis across all studies, pathogens
isolated were more frequently bacterial (74%) than viral (19%). Compared with the 
15 international studies, U.S. studies recorded a similar isolation rate for bacterial
(73% vs. 74%) and higher isolation rate for viral pathogens (23% vs. 17%). Twenty-
three studies included data on the speciﬁ c bacterial pathogens cultured. Based on a 
ﬁ xed-effects meta-analysis of patients in these studies, S. pneumoniae and Haemophi-
lus inﬂ uenzae were isolated with similar frequency (35% vs. 36%) and Moraxella
catarrhalis at 6%. Slightly higher isolation rates of M. catarrhalis (10%) and lower 
rates of H. inﬂ uenzae (31%) were observed in U.S. patients, compared with interna-
tional patients. CONCLUSIONS: Bacterial pathogens are frequently associated with
AOM in pediatric populations worldwide and were isolated 3-times more often than 
viral pathogens. S. pneumoniae and H. inﬂ uenzae are the bacterial pathogens most
commonly isolated in AOM cases, with nearly equal frequency. A vaccine that 
addresses more than one cause of AOM would be expected to greatly reduce the 
clinical and economic burden associated with this common condition.
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OBJECTIVES: Risks and beneﬁ ts of TNF-alpha inhibitors are often presented using 
statistical descriptions that are difﬁ cult to directly translate for patients into a clini-
cally-meaningful context. The objective of this study was to illustrate the risks and 
beneﬁ ts of TNF-alpha inhibitors in relation to risks that patients understand. 
METHODS: We performed a number needed to treat analysis for psoriasis patients 
on TNFalpha inhibitors via a Medline and Embase search. We determined the number
needed to beneﬁ t and the number needed to harm with TNF-alpha inhibitor treatment. 
We compared the risk of serious adverse events (SAE) from treatment with a TNF-
alpha inhibitor to the risk of death from driving a car. The risk analyses were limited
to tuberculosis, lymphoma, and demyelinating disease. RESULTS: The numbers
needed to beneﬁ t were 2.1 for etanercept, 1.4 for inﬂ iximab, and 1.6 for adalimumab.
Depending on adverse event, the numbers needed to harm ranged from 380 to 360,000 
treated patients per year. Screening prior to the initiation of TNF-alpha inhibitor 
therapy reduces risk of tuberculosis. Patients are about as likely to die in a car accident
as have a serious adverse event from TNF-alpha inhibitor treatment. CONCLU-
SIONS: All 3 of the TNF-alpha antagonists have remarkable efﬁ cacy in patients with 
severe psoriasis. The risks of serious adverse events are relatively rare and comparable 
to risks patients take on a regular basis such as driving a car. For severe psoriasis, the 
beneﬁ ts of TNF-alpha inhibitors may greatly outweigh the risks for many patients.
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OBJECTIVES: To assess the cost differences between adalimumab and etanercept for
chronic plaque psoriasis. METHODS: A model was constructed to compare the drug
acquisition costs for adalimumab and etanercept for chronic plaque psoriasis for a
hypothetical primary care trust. The number of patients eligible for anti-TNF treat-
ment was taken from published sources. Patients were assumed to receive either etan-
ercept intermittently, mixed intermittent and continuous, continuous, or continuous 
adalimumab. Market research demonstrated that about 36% of patients are likely to 
receive continuous etanercept. Adalimumab, in contrast can not be used intermittently. 
Costs were estimated from a UK payer perspective. The time horizon is three years.
RESULTS: We estimated that the hypothetical PCT would cover 250,000 people, 
which is approximately the average size of a PCT in the UK. Of these 195,000 would 
be q 18 years of age. thirty-ﬁ ve patients would meet the criteria for either adalimumab
or etanercept. Providing that all patients would receive intermittent etanercept this 
would cost the NHS GBP 722,190, if 36% receive continuous etanercept and the rest 
intermittent etanercept it would cost GBP 816,453, whilst if all patients would receive 
continuous etanercept it would cost GBP 975,975. All patients receiving continuous 
adalimumab would cost GBP 1,001,000. CONCLUSIONS: Our model found poten-
tial for cost savings for PCTs from using etanercept instead of adalimumab, within 
the recommended patient groups for chronic plaque psoriasis. Savings will be increas-
ingly important if the proportion of eligible patients who receive treatment increases 
from the current level.
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OBJECTIVES: To compare the use of prostaglandin analogues namely, Bimatoprost,
Travoprost and Latanoprost, in the treatment of glaucoma by conducting a cost 
effectiveness analysis considering medication related adverse event and patient-
persistence as indirect costs. METHODS: The study was conducted from a third-
party payer’s (Medicare) perspective with a time-frame of 12 months. Literature 
review was conducted to estimate medical-visit costs, average reduction in intra-ocular
pressure (IOP) in mm Hg, medications related adverse event and patient-persistence
to the pharmacotherapy. Average wholesale price (AWP) for the drug considered
(obtained from the REDBOOK-2007), mean number of drops per bottle (according 
to the best instillation method), days per bottle, and annual usage of bottles for these 
drugs were also obtained from published literature to determine the annual cost
associated with prostaglandin pharmacotherapy. DATA (version 3.0) software package 
was used to perform the decision analysis. Incremental cost-effectiveness ratios (ICER)
were calculated using intra-ocular-pressure reduction as efﬁ cacy estimate. Sensitivity 
analyses were conducted by changing the cost information by 25% to account for the 
variation in drug administration. A discounting rate of 5% was used to project all 
cost estimates to year 2008. RESULTS: The decision-analysis indicated Travoprost 
to be slightly inexpensive among the three prostaglandins (expected value $616.33),
followed by Bimatoprost (expected value $618.73) and Latanoprost (expected 
value $626.29). Compared with Latanoprost, Travoprost and Bimatoprost provided
a higher IOP-reduction with ICER of $(9.96) and $(7.56) respectively. Results
of sensitivity analyses were robust to the decision analysis performed. CONCLU-
SIONS: Based on our analysis Travoprost and Bimatoprost was more cost-effective 
than Latanoprost. Health care decision-makers should consider the effect of adverse 
drug events and persistency proﬁ les on the direct medical costs to prioritize the pros-
taglandin analogues for long-term treatment of glaucoma. Further, analyses using 
adherence data for speciﬁ c patient groups can provide valuable information to decision
makers.
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OBJECTIVES: To calculate the cost per clinical success (CS) in the antibiotic treatment 
for complicated skin and skin-structure infections (CSSI) in Mexican Social Security
Institutions in Mexico. METHODS: The use of either i.v. Daptomycin (DAP), i.v. 
Vancomycin (VAN) or i.v. Linezolid (LIN) as ﬁ rst-line and second-line antibiotic
therapy was compared in a cost-effectiveness study. Data was collected from a sys-
tematic review which included the most recent published articles measuring clinical
improvement, length of stay at hospital services and adverse events due to the use of 
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any of three evaluated antibiotic. The use of resources as estimated according to 
Mexican Social Security Institutions expenses and its use were simulated within a 
decision tree with Bayesian approach. The model considered clinical success as the
best health state, reached in either short hospital stay or long hospital stay and a 
therapeutic failure of ﬁ rst-line antibiotic therapy (DAP, VAN or LIN) which caused 
the use of a second-line antibiotic therapy (DAP or LIN depending on ﬁ rst election). 
Costs calculation considered hospital stay, concomitant medication and selected anti-
biotic treatment. Results were evaluated with incremental analysis and one-way sen-
sitivity analysis of the most uncertain variables were also conducted. RESULTS: The
use of i.v. Daptomycin as ﬁ rst-line therapy followed by i.v. Linezolid in case of thera-
peutic failure resulted in the lowest total cost per clinical success (DAP-LIN: $3255.00 
USD/CS; VAN-DAP: $3310.00 USD/CS; VAN-LIN: $3310.00 USD/CS; LIN-DAP: 
$3423.00 USD), attaining a 98% of CS. The sensitivity analysis varying clinical success 
rates of every evaluated alternative showed robustness of base study. CONCLU-
SIONS: Daptomycin is the most cost-effective alternative in the treatment of CSSI 
when used as ﬁ rst-line antibiotic therapy since its use reduces the length of hospital 
stay reducing expenses of public health system budget in Mexico.
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OBJECTIVES: To determine the most cost-effective antibiotic treatment for compli-
cated skin and skin-structure infections (CSSI) in public health care institutions in 
Mexico. METHODS: A cost-effectiveness study with institutional perspective was 
conducted comparing the use of either i.v. Daptomycin (DAP), i.v. Vancomycin (VAN) 
or i.v. Linezolid (LIN) as ﬁ rst-line antibiotic therapy. Data collection obtained with a
systematic review considered efﬁ cacies measured as clinical improvement, length of 
stay at hospital services and adverse events. A decision tree with Bayesian approach
was designed to simulate the use of resources based on patient’s prognosis due to use 
one of the evaluated alternatives. Patients are supposed to reach either of two different 
health states: clinical success and therapeutic failure, the former can be attained 
through a short hospital stay or a long hospital stay depending on selected treatment, 
the latter requires the administration of a second-line antibiotic therapy increasing 
cost. Costs calculation considered hospital stay, concomitant medication and selected
antibiotic treatment. Results were evaluated with incremental analysis and one-way 
sensitivity analysis of the most uncertain variables were also conducted. RESULTS:
The use of i.v. Daptomycin results in the lowest total cost (DAP: $3,078.00 USD; 
VAN: $3,159.00 USD; LIN: $3,173.USD) and the lowest cost per clinical success (CS) 
(DAP: $3,405.00 USD/CS; VAN:$3,550.00 USD/CS; LIN:$3,870.00 USD/CS) com-
pared with i.v. Vancomycin or i.v. Linezolid. The sensitivity analysis varying clinical 
success rates of every evaluated alternative showed robustness of base study. CON-
CLUSIONS: Daptomycin is the most cost-effective alternative in the treatment of CSSI 
when used as ﬁ rst-line antibiotic therapy since its use reduces the length of hospital 
stay reducing expenses of public health system budget in Mexico.
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REDUCTION OF ACUTE OTITIS MEDIA IN CHILDREN: A COST-
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VACCINE (PHID-CV) COMPARED WITH THE 7-VALENT 
PNEUMOCOCCAL VACCINE (PCV-7)
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OBJECTIVES: Acute otitis media (AOM) is a prevalent pediatric condition, affecting
approximately 80% of children by three years of age. Routine immunization programs 
include 7-valent Pneumococcal conjugate vaccine (PCV-7), associated with a reduction
of AOM events caused by Streptococcus pneumoniae. The objective of this study was
to compare the costs and effects of PCV-7 with PHiD-CV, a newly approved in Canada
Pneumococcal non-typeable Haemophilus inﬂ uenzae Protein D-conjugate vaccine 
employing an active protein D-carrier associated with reduction of nontypeable Hae-
mophilus Inﬂ uenzae (NTHi) AOM. METHODS: A steady-state, population-based 
model with a one-year time horizon was developed, and calibrated with Canadian
epidemiologic and demographic data, to investigate the costs and effects associated 
with AOM episodes across the Canadian population. A 4-dose schedule for PHiD-CV 
vaccination was compared with a 4-dose schedule for PCV-7 vaccination. The base-
case included herd-protection for invasive pneumococcal disease and serotype 6A cross
protection. A health care system perspective was taken with the assumption of 100% 
vaccination coverage. RESULTS: Compared with PCV-7, vaccination with PHiD-CV 
could prevent an additional 170,951 ambulatory visits for AOM, 144,454 antibiotic 
prescriptions for AOM, and 9,830 hospitalizations for myringotomy per year. With 
PCV-7 the total direct costs associated with AOM are $119.8 million of which $16.9
million could be off-set by implementation of routine vaccination with PHiD-CV.
CONCLUSIONS: Based on the base-case analysis, inclusion of PHiD-CV in routine
immunization programs across Canada would be cost-saving to the health care system
compared with PCV-7. PHiD-CV offers substantial beneﬁ ts in terms of reduced ambu-
latory visits, antibiotic prescriptions and hospitalizations for AOM, a highly prevalent 
childhood condition.
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OBJECTIVES: Psoriasis is a chronic debilitating immune-mediated inﬂ ammatory
disease, with no cure, affecting an estimated one million Canadians. Studies show that
up to 85% of psoriasis is of plaque type and up to 25% of sufferers have either moder-
ate or severe disease. There are no reliable estimates of the economic burden of pso-
riasis in Canada. The objective is to estimate the economic burden of moderate to
severe chronic plaque psoriasis in Canada in 2008, inclusive of direct medical and
non-medical, and lost productivity costs. METHODS: Using a cross-sectional design, 
data were collected on 90 patients diagnosed with moderate or severe chronic plaque 
psoriasis in three dermatology clinics (British Columbia, Ontario, and Quebec). Data
were obtained from three sources: clinic charts determining medical resources utilized 
for treatment; patient questionnaires eliciting information on non-medical resources
utilized, lost productivity, and the impact on quality of life (QoL) using the Dermatol-
ogy Quality of Life Index (DLQI); and unit costs (all in CDN$2008) from published
sources. RESULTS: The estimated mean annual costs of treating patients with moder-
ate to severe chronic plaque psoriasis was $7966/patient, of which $4524 (95% con-
ﬁ dence interval (CI): $2246 to $6802) was due to direct medical and non-medical
costs, and $3442 (95% CI: $1293 to $5590) was due to lost productivity. The esti-
mated mean DLQI of 6.7 is reﬂ ective of a moderate impact on QoL in moderate to
severe psoriasis patients. CONCLUSIONS: Extrapolating these costs to the estimated 
number of affected Canadians means that moderate to severe psoriasis costs on the
order of $961.3 million (95% CI: $477.3 million to $1.4 billion) in direct medical 
and non-medical costs annually. The total cost to society is approximately $1.7 billion
(95% CI: $752.0 million to $2.6 billion). This economic burden coupled with the
QoL effect indicates the need for more efﬁ cient and long-term control.
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OBJECTIVES: Severe Chronic Hand Eczema (CHE) or Chronic Hand Dermatitis
(CHD), is characterized by thick scaly skin causing painful ﬁ ssures, erythema, itching, 
blustering and oedema. Severe CHE/CHD is often unresponsive to conventional 
topical corticosteroids and results in substantial occupational, personal, and psycho-
logical disability. There is currently a lack of information regarding the economic
burden of CHE/CHD in Canada. METHODS: A dynamic Excel model was devel-
oped to estimate the cost of treating adults with severe CHE in Canada. Epidemiologi-
cal/clinical data were derived from systematic literature searches. A Delphi panel of 
dermatologists provided estimates of resource utilization and validated epidemiologi-
cal/clinical rates. Given the impact on lost productivity, a pseudo societal perspective 
was chosen; out of pocket expenses (travel and non-prescription pharmacotherapies)
were excluded from the analysis. Unit costs were derived from Ontario standard lists
and reported as 2008 Canadian dollars. RESULTS: In 2008 the estimated adult popu-
lation was 26 million. From the literature it was determined that 10% of adults may 
be affected by CHE, of those 6.7% may have severe CHE/CHD. Asscessing 50% of 
these patients don’t adequately respond to topical corticosteroids, an estimated 87,200 
Canadians have severe CHE being refractory to topicals. Treatment costs, including 
lost productivity, was calculated to be $737 million per annum. Even assuming current 
second-line treatment options are 100% effective, the cost of severe CHE was esti-
mated to be $390 million per annum. CONCLUSIONS: This study estimated the costs 
of severe CHE/CHD unresponsive to topical corticosteroids in Canada ranges from 
$390–$737 million per annum. The majority of costs comes from lost productivity
due to disease and accessing treatment.
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OBJECTIVES: The purpose of this study was to assess the cost-utility of posterior
lamellar keratoplasty techniques, including deep lamellar endothelial keratoplasty 
(DLEK), Descemet stripping endothelial keratoplasty (DSEK) and Descemet stripping
automated endothelial keratoplasty (DSAEK), in the treatment of corneal endothelial 
diseases. METHODS: This cost-utility analysis was performed from a Canadian health
system perspective over a lifetime period. A Markov model was constructed to 
compare the cost per quality adjusted life year (QALY) associated to penetrating kera-
toplasty (PK) and lamellar keratoplasty techniques (DLEK, DSEK and DSAEK). The 
Markov model included all major health states relevant to patients scheduled for
corneal transplantation: waiting for transplantation, surviving graft with or without 
